- Filter by
- Categories
- Tags
- Authors
- Show all
- All
- Allergy&Clinical Immunology
- Anesthesiology
- Business of Medicine
- Cardiology
- Critical Care
- Dental&Oral Health
- Dermatology
- Diabetes&Endocrinology
- Emergency Medicine
- Family Medicine/Primary Care
- Gastroenterology
- General Surgery
- Hematology-Oncology
- HIV/AIDS
- Hospital Medicine
- Infectious Diseases
- Internal Medicine
- Med Students
- Medscape Today
- Nephrology
- Neurology&Neurosurgery
- News
- News Alert
- None
- Nursing
- Ob/Gyn&Women's Health
- Ophthalmology
- Orthopaedics
- Pathology&Lab Medicine
- Pediatrics
- Pharmacist
- Plastic Surgery&Aesthetic Medicine
- Psychiatry
- Public Health&Prevention
- Pulmonary Medicine
- Radiology
- Rheumatology
- Transplantation
- Urology
October 3, 2022
Published by Med Search on October 3, 2022
Categories
Effective communication among ANDA applicants, DMF holders, and FDA is essential for reducing the likelihood of potential problems that could delay approvals. The reauthorization of the […]
October 3, 2022
Published by Med Search on October 3, 2022
Categories
Controlled correspondence is a correspondence submitted to FDA by or on behalf of a generic drug manufacturer or related industry requesting information on a specific element […]
October 3, 2022
Published by Med Search on October 3, 2022
Categories
GDUFA III includes several enhancements to the abbreviated new drug application (ANDA) assessment process to maximize the efficiency and utility of each assessment cycle. These enhancements […]
October 3, 2022
Published by Med Search on October 3, 2022
Categories
The Pre-Abbreviated New Drug Application (Pre-ANDA) Program is designed to assist prospective generic drug applicants in developing more complete submissions, promote a more efficient and effective […]
October 3, 2022
Published by Med Search on October 3, 2022
Categories
On August 18, 2017, the President signed into law the Food and Drug Administration Reauthorization Act (FDARA). This new law includes the reauthorization of the Prescription […]
October 3, 2022
Published by Med Search on October 3, 2022
Categories
Under the Prescription Drug User Fee Act (PDUFA) VII Commitment Letter[1], FDA is creating the Split Real Time Application Review (STAR) pilot program. Overview FDA […]
October 3, 2022
Published by Med Search on October 3, 2022
Categories
Afinitor (everolimus) Afinitor Disperz (everolimus) Rapamune (sirolimus) Zortress (everolimus) Drug interaction FDA is evaluating the need for regulatory action. Bavencio (avelumab) Imfinzi (durvalumab) Jemperli (dostarlimab-gxly) Keytruda […]
October 1, 2022
Published by Med Search on October 1, 2022
Categories
FDA is committed to enhancing the U.S. drug safety system and envisions the Sentinel System will strengthen FDA’s post-market surveillance capabilities. To support this effort, FDA […]
September 30, 2022
Published by Med Search on September 30, 2022
Categories
On September 30, 2022, the Food and Drug Administration granted accelerated approval to futibatinib (Lytgobi, Taiho Oncology, Inc.) for adult patients with previously treated, unresectable, locally […]
Prev page
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144
Next page